(Q34210163)

31 July 2017

title

Prostate-specific antigen testing across the spectrum of prostate cancer (English)

1 reference

31 July 2017

1 reference

Mark R Haythorn

1

1 reference

31 July 2017

Richard J Ablin

series ordinal

2

1 reference

31 July 2017

publication date

1 August 2011

1 reference

31 July 2017

published in

Biomarkers in Medicine

1 reference

31 July 2017

volume

5

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

515-526

1 reference

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

31 July 2017

cites work

1 reference

Screening for prostate cancer: have you had your cholesterol measured?

21 January 2018

1 reference

Precipitating antigens of the normal human prostate.

21 January 2018

1 reference

Immunologic studies of normal, benign, and malignant human prostatic tissue

21 January 2018

1 reference

Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.

21 January 2018

1 reference

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml

21 January 2018

1 reference

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

21 January 2018

1 reference

Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up

21 January 2018

1 reference

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

21 January 2018

1 reference

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

21 January 2018

1 reference

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

A retrospective and prospective overview of prostate-specific antigen

21 January 2018

1 reference

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

21 January 2018

1 reference

Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.

21 January 2018

1 reference

A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia

21 January 2018

1 reference

Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.

21 January 2018

1 reference

Genetic correction of PSA values using sequence variants associated with PSA levels

21 January 2018

1 reference

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

21 January 2018

1 reference

Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments.

21 January 2018

1 reference

Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis

21 January 2018

1 reference

Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature

21 January 2018

1 reference

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

21 January 2018

1 reference

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

21 January 2018

1 reference

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal

21 January 2018

1 reference

Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?

21 January 2018

1 reference

PSAdynia and other PSA-related syndromes: a new epidemic--a case history and taxonomy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.11.53

1 reference

31 July 2017

1 reference